A 32-year-old woman presents to the emergency department with a 3-day history of severe vesicular rash in a dermatomal distribution on the left thorax, accompanied by intense burning pain. She is immunocompetent, afebrile, and vital signs are stable. PCR of vesicular fluid confirms varicella-zoster virus (VZV). What is the most appropriate immediate next step in management?

Explanation

## Clinical Context This is a case of herpes zoster (shingles) in an immunocompetent adult presenting within 72 hours of rash onset. Early antiviral therapy is the standard of care to reduce pain duration and post-herpetic neuralgia (PHN) risk. ## Why Oral Valacyclovir Is Correct **Key Point:** In immunocompetent patients with uncomplicated herpes zoster, oral antiviral therapy (valacyclovir or famciclovir) is the first-line treatment, provided it is started within 72 hours of rash onset. **High-Yield:** Valacyclovir is a prodrug of acyclovir with superior oral bioavailability (~55% vs ~15% for acyclovir). Standard dosing is 1 g (1000 mg) three times daily for 7 days. **Clinical Pearl:** Early oral antiviral therapy in herpes zoster reduces: - Duration of acute pain - Incidence and severity of post-herpetic neuralgia (PHN) - Duration of viral shedding ## Management Algorithm for Herpes Zoster ```mermaid flowchart TD A[Confirmed VZV Zoster]:::outcome --> B{Immunocompetent?}:::decision B -->|Yes| C{Within 72 hrs of rash?}:::decision B -->|No| D[IV Acyclovir]:::action C -->|Yes| E[Oral Valacyclovir 1g TDS x7d]:::action C -->|No| F[Consider oral therapy if PHN risk high]:::action E --> G[Analgesia + supportive care]:::action D --> G G --> H[Monitor for complications]:::action ``` **Table: Antiviral Options for Herpes Zoster** | Agent | Route | Dose | Bioavailability | First-line? | | --- | --- | --- | --- | --- | | Valacyclovir | Oral | 1 g TDS × 7 d | 55% | Yes (immunocompetent) | | Famciclovir | Oral | 500 mg TDS × 7 d | 77% | Yes (alternative) | | Acyclovir | Oral | 800 mg 5× daily × 7 d | 15% | No (poor absorption) | | Acyclovir | IV | 10–15 mg/kg Q8H | 100% | Yes (immunocompromised) | ## Why Other Options Are Incorrect **Intravenous acyclovir** is reserved for immunocompromised patients, disseminated disease, CNS involvement, or severe ocular involvement—not routine zoster in immunocompetent patients. **Topical acyclovir** has minimal systemic absorption and does not reduce PHN risk; it is insufficient monotherapy. **Lumbar puncture** is not indicated in uncomplicated dermatomal zoster without meningeal signs (headache, neck stiffness, photophobia). VZV meningitis is rare in immunocompetent hosts and would be suspected clinically.